Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01316276|
Recruitment Status : Completed
First Posted : March 16, 2011
Results First Posted : July 26, 2019
Last Update Posted : June 17, 2020
|Condition or disease||Intervention/treatment||Phase|
|Cystic Fibrosis||Drug: Liposomal amikacin for inhalation||Phase 3|
This was a long-term, open-label, multi-cycle extension study for patients in the Phase 3 study TR02-108 and TR02-109 who had successfully completed the 168-day study period and met study safety criteria. As this was a safety and tolerability long-term extension study, no sample size calculations were performed. All patients who completed TR02-108, were compliant with the study protocol, and did not meet any of the criteria listed for study discontinuation (safety reasons or non-compliance) were able to participate in this open-label study.
The end of study visit for TR02-108 was to serve as the baseline study visit (Day 1) for TR02-110 if the patient had signed the informed consent at least 4 days prior to the end of study visit and met all safety criteria for TR02-110. If the end of study visit was not used as the baseline visit, a separate baseline visit (Day 1) was to be performed within 14 days of completing TR02-108.
Patients were to receive a delivered dose of 590 mg LAI QD via a PARI Investigational eFlow® Nebulizer System (eFlow®) for 28 days followed by a 28-day off-treatment period. This cycle (28 days on treatment, 28 days off treatment) was to be repeated for up to 12 cycles. The study was implemented as 2 consecutive extension periods, each consisting of 48 weeks (approximately 12 months). Patients were re-consented for the second extension period at the completion of the first extension period. The total study period was up to 96 weeks (approximately 2 years).
During the first 28 days of treatment, patients were evaluated at the study site bi-weekly for safety, tolerability and efficacy. Thereafter, for the duration of the study, patients were evaluated at the study site on the first and last days of dosing during the on-treatment periods. During the study, starting with the off-treatment period of Cycle 1, patients were contacted by telephone once during every 28-day period to assess safety. A final site visit occurred 28 days after last dose of LAI. Arikace™, Arikayce™,Liposomal Amikacin for Inhalation (LAI), and Amikacin Liposome Inhalation Suspension (ALIS) may be used interchangeably throughout this study and other studies evaluating amikacin liposome inhalation suspension.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||206 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Long Term Safety and Tolerability Study of Open-Label Liposomal Amikacin for Inhalation (ARIKACE™) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa|
|Actual Study Start Date :||October 5, 2012|
|Actual Primary Completion Date :||July 16, 2015|
|Actual Study Completion Date :||July 16, 2015|
590 mg LAI QD via a PARI Investigational eFlow® Nebulizer System (eFlow®) for 28 days followed by a 28-day off-treatment period. This cycle (28 days on treatment, 28 days off treatment) was to be repeated for up to 12 cycles, divided into 2 periods of 6 cycles each (approximately 12 months each).
Drug: Liposomal amikacin for inhalation
- Treatment Emergent Adverse Events (TEAEs) up to Day 672 [ Time Frame: From Study Initiation up to Day 672 ]Treatment emergent adverse events including serious adverse events (SAE) and adverse events (AE) leading to permanent discontinuation of study drug
- Laboratory Abnormalities up to Day 672 [ Time Frame: Baseline, Day 377 and Day 672 ]
- Number of Subjects with Grade 3 or Higher Abnormalities in Clinical Laboratory Values
- Number of Subjects with Grade 3 or Higher Hematology Laboratory Value Abnormalities
- Number of Subjects with Grade 3 or Higher Chemistry Laboratory Value Abnormalities
- Acute Tolerability as Measured by Pulmonary Function Test (PFT) Changes Pre to Post Dose [ Time Frame: Day 1, Day 84, Day 196, Day 281, Day 337, Day 449, Day 532 and Day 644 ]Number of Subjects with a >15% in Decline in Forced Expiratory Volume in 1 Second (FEV1) From Predose to Postdose
- Respiratory Rate: Change From Baseline to Day 672 [ Time Frame: From Study Initiation up to Day 672 ]Respiratory rate was recorded at every visit as per standard practice at each investigational site.
- Heart Rate: Change From Baseline From Day 672 [ Time Frame: From Study Initiation up to Day 672 ]Pulse rate (after at least 5-minute rest) was recorded at every visit as per standard practice at each investigational site.
- Systolic BP: Change From Baseline at Day 672 [ Time Frame: From Study Initiation up to Day 672 ]Sitting blood pressure was recorded at every visit as per standard practice at each investigational site.
- Diastolic BP: Change From Baseline at Day 672 [ Time Frame: From Study Initiation up to Day 672 ]Sitting blood pressure was recorded at every visit as per standard practice at each investigational site.
- Body Temperature: Change From Baseline at Day 672 [ Time Frame: From Study Initiation up to Day 672 ]Body temperature was recorded at every visit as per standard practice at each investigational site.
- Oxygen Saturation: Change From Baseline at Day 672 [ Time Frame: From Study Initiation up to Day 672 ]Change in oxygen saturation as measured with pulse oximetry was performed via finger probes placed on the extremity opposite arterial lines and noninvasive blood pressure monitoring devices so that pulsatile flow was not interrupted.
- Minimum Inhibitory Concentrations (MICs) for Pseudomonas Aeruginosa (Pa) and Burkholderia Species From Day 1 to Days 169, 337, 505 and 672 [ Time Frame: Day 1, Day 169, Day 337, Day 505 and Day 672 ]
Sputum was cultured for quantitative microbiological evaluation of Pa and Burkholderia species in designated regional central microbiology laboratories. A standard microbiology protocol was used for Pa culture and identification for each morphologically distinct Pa phenotype.
Although planned in the Statistical Analysis Plan (SAP), MICs of amikacin Burkholderia species were not determined due to the small number of isolates with Burkholderia. In addition, susceptibility testing of isolates of Pa and Burkholderia species against a panel of commonly used antipseudomonal antibiotics was planned but was not performed.
The results of the following analyses for Pa isolates are presented.
- Frequency of MIC of Amikacin
- Frequency of MIC of Tobramycin
MIC50: lowest concentration of the antibiotic at which 50 % of the isolates were inhibited.
- Evaluation of Audiology [ Time Frame: Day 337 and Day 672 ]Hearing was evaluated using air conduction [AC]. Bone conduction was required if the AC testing demonstrated a decrease of >20 decibels [dB]. Hearing loss was categorized using Common Terminology Criteria for Adverse Events as follows: GRADE 1 (best): Adults [A] on a Monitoring Program [MP]: Threshold shift of 15-25 dB; Pediatric [P]: Threshold shift >20 dB at 8 kilohertz (kHz). GRADE 2: [A] on a MP: Threshold shift of >25 dB; [A] not enrolled in MP: hearing loss; hearing aid/intervention not indicated; [P]: Threshold shift >20 dB at 4 kHz and above. GRADE 3: [A] enrolled in MP: Threshold shift of >25 dB; therapeutic intervention indicated; [A]: Not enrolled in MP: hearing aid/intervention; [P]: therapeutic intervention, including hearing aids: Threshold shift >20 dB at 3 kHz and above; additional speech-language related services. GRADE 4 (worst): [A]: Profound bilateral hearing loss; non-serviceable hearing; [P]: cochlear implant & additional speech-language related services.
- Change in Serum Creatinine Throughout the Study [ Time Frame: Baseline, Day 337 and Day 672 ]
- Common Terminology Criteria for Adverse Events (CTCAE) Grade 1: > ULN-1.5 × ULN
- CTCAE Grade 2: > 1.5 × ULN to 3.0 x ULN
- Percent Change in FEV1 Throughout the Study [ Time Frame: Baseline, Day 337 and Day 672 ]Percent Change From Baseline in Predose FEV1
- Number of Subjects Experiencing a Protocol Defined Pulmonary Exacerbation [ Time Frame: From Study Initiation up to Day 700 ]For number of subjects to first protocol-defined pulmonary exacerbation, follow-up time began at the first dose of study drug (Day 1) and ended no later than Day 700 (28-day follow up).
- Number of Subjects Initiating Treatment. [ Time Frame: From Study Initiation up to Day 672 ]
The number of subjects initiating antipseudomonal therapy for protocol-defined pulmonary exacerbation confirmed by the investigator, and for investigator-defined pulmonary exacerbation were summarized.
The data presented below is the Frequency of Systemic or Inhaled Antipseudomonal Therapy for Protocol-defined Pulmonary Exacerbations Confirmed by Investigator
- Time to First Use of Any New Antibiotic Treatment, Censoring at Date of Last Contact
- Number of Participants Who Received Antipseudomonal Antibiotic Treatment for Protocol Defined Pulmonary Exacerbation [ Time Frame: From Study Initiation up to Day 700 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01316276
|Study Director:||Gina Eagle, MD||Insmed Incorporated|